120072-59-5

Basic information

• Product Name: 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
• Synonyms: SC-41930; 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
• CAS NO: 120072-59-5
• Molecular Formula: C₂₈H₃₆O₇
• Molecular Weight: 484.5812
• Mol File: 120072-59-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 658°C at 760 mmHg
• Flash Point: 214.1°C
• Density: 1.156g/cm³
• Vapor Pressure: 3.27E-18mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid(120072-59-5)
• EPA Substance Registry System: 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid(120072-59-5)

Safety Data

• Hazardous Substances Data: 120072-59-5(Hazardous Substances Data)

Upstream product

• 98193-34-1 methyl 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylate 
• 98193-35-2 methyl 7-[3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylate 
• 79557-63-4 3-(2-propyl-3-hydroxy-4-acetylphenoxy)-1-iodopropane 
• 79558-02-4 1-[4-(3-chloropropoxy)?2-hydroxy-3-propylphenyl]ethanone 
• 40786-69-4 1-(2,4-dihydroxy-3-propylphenyl)ethanone 
• 120072-58-4 methyl ester of 7-<3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid 

Relevant articles and documents

Method of diminishing the adverse effects of interleukin-2

A method and composition for preserving or enhancing the beneficial effects of interlude-2 (IL-2) while simultaneously mitigating the adverse effects of IL-2 on a subject is disclosed. The method involves administering an amount of a leukotriene B4 (LTB4) antagonist, preferably a LTB4 receptor antagonistic, to a subject exhibiting adverse pharmacological effects due to exogenous IL-2, where the amount administered to the subject is sufficient to decrease the IL-2 induces adverse effects. Also disclosed is an article of manufacturing comprising a composition of the leukotriene B4 antagonist in combination with labeling instructions for treatment. Also disclosed is a method for preparing a pharmaceutical composition. Generally the LTB4 antagonist will reduce the IL-2-induced adverse effects while preserving or enhancing the anti tumor, antiviral, or immunostimulatory effects of IL-2, thereby improving the therapeutic index of IL-2.

Leukotriene B4 antagonists

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof STR1 wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl; R1 is alkyl; R2 represents alkyl from 1 to 5 carbon a

LEUKOTRIENE B4 ANTAGONISTS

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof STR1 wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl;R 1 is alkyl; R 2 is hydrogen, alkyl;R 6 is alkyl;